AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28464887 — intervention group
Group type: COMPARATOR
Intervention: Healthy Habits Control Condition with face-to-face, tailored attention control '5-2-1-0' counseling focusing on improving child's health.
Number of subjects: 0
Study 28464887 — intervention group
Group type: EXPERIMENTAL
Intervention: SBIRT Condition
Number of subjects: 0
Study 28464887 — intervention group
Group type: COMPARATOR
Intervention: Healthy Habits Control Condition
Number of subjects: 0
Study 26120056 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous morphine infusion (10 μg/kg/h)
Number of subjects: 89
Study 26120056 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 24930359 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline (titrated up to 1 mg)
Number of subjects: 26
Study 24930359 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 21818622 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous injection of 50 U/Kg of rHuEPO
Number of subjects: 14
Study 19254669 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy
Number of subjects: 0
Study 19254669 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac contractility modulation
Number of subjects: 0
Study 17764013 — intervention group
Group type: EXPERIMENTAL
Intervention: Boswellia serrata extract (BSE) 400 mg three times daily for 6 weeks
Number of subjects: 31
Study 17764013 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 17764013 — intervention group
Group type: EXPERIMENTAL
Intervention: Boswellia serrata extract (BSE)
Number of subjects: 31
Study 17764013 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label BSE therapy
Number of subjects: 31
Study 15226088 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (alpha-tocopherol acetate, 400 mg/day)
Number of subjects: 40
Study 15226088 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 11794432 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous amiodarone
Number of subjects: 550
Study 11794432 — intervention group
Group type: EXPERIMENTAL
Intervention: Other antiarrhythmics
Number of subjects: 550
Study 11794432 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 550
Study 9818751 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime 2 g bd
Number of subjects: 400
Study 9818751 — intervention group
Group type: COMPARATOR
Intervention: Imipenem‐cilastatin 1 g tds (50 mg/kg/day)
Number of subjects: 400
Study 9818751 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime
Number of subjects: 400
Study 9818751 — intervention group
Group type: COMPARATOR
Intervention: Imipenem‐cilastatin
Number of subjects: 400
Study 8110569 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% EMLA cream 2.5 g for 30 min
Number of subjects: 120
Study 8110569 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% EMLA cream 2.5 g for 60 min
Number of subjects: 120
Study 8110569 — intervention group
Group type: EXPERIMENTAL
Intervention: amethocaine cream 1 g (5% w/w) for 30 min
Number of subjects: 120
Study 8110569 — intervention group
Group type: EXPERIMENTAL
Intervention: amethocaine cream 1 g (5% w/w) for 60 min
Number of subjects: 120
Study 3297679 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% with 200 micrograms fentanyl (B:F 200 group)
Number of subjects: 161
Study 3297679 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.5% with normal saline (B:F o group)
Number of subjects: 161
Study 29643155 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate continuous femoral nerve block via catheter
Number of subjects: 118
Study 29643155 — intervention group
Group type: COMPARATOR
Intervention: Standard analgesia (standard care)
Number of subjects: 118
Study 27513363 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive program (n=46)
Number of subjects: 87
Study 27513363 — intervention group
Group type: COMPARATOR
Intervention: Psycho-educational self-help website (n=41)
Number of subjects: 87
Study 26714758 — intervention group
Group type: EXPERIMENTAL
Intervention: Insecticide-treated bed nets (ITNs) from birth (group A, n = 45)
Number of subjects: 90
Study 26714758 — intervention group
Group type: COMPARATOR
Intervention: Insecticide-treated bed nets (ITNs) from age 6 months (group B, n = 45)
Number of subjects: 90
Study 23733232 — intervention group
Group type: EXPERIMENTAL
Intervention: Alphacypermethrin (ACYP) pour-on treatment
Number of subjects: 20
Study 23733232 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group (C-group)
Number of subjects: 20
Study 20066735 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic mixture of Bifidobacterium longum (BB536) and Lactobacillus johnsonii (La1) at a dose of 10^9, given orally 2 doses/day for 3 days preoperatively and continued postoperatively from day 2 to day 4
Number of subjects: 31
Study 20066735 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic mixture of Bifidobacterium longum (BB536) and Lactobacillus johnsonii (La1) at a dose of 10^7, given orally 2 doses/day for 3 days preoperatively and continued postoperatively from day 2 to day 4
Number of subjects: 31
Study 20066735 — intervention group
Group type: COMPARATOR
Intervention: Placebo, given orally 2 doses/day for 3 days preoperatively and continued postoperatively from day 2 to day 4
Number of subjects: 31
Study 20066735 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic mixture of Bifidobacterium longum (BB536) and Lactobacillus johnsonii (La1) at a dose of 10^9
Number of subjects: 31
Study 19363849 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed combination of perindopril-indapamide
Number of subjects: 11140
Study 19363849 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11140
Study 19648155 — intervention group
Group type: COMPARATOR
Intervention: 0 ng ml(‐1) remifentanil
Number of subjects: 24
Study 19648155 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 ng ml(‐1) remifentanil
Number of subjects: 24
Study 19648155 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 ng ml(‐1) remifentanil
Number of subjects: 24
Study 15811769 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA granules (n = 21, BCAA group)
Number of subjects: 43
Study 15811769 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 22)
Number of subjects: 43
Study 11566624 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF-alpha and NO donors in mitogen-activated, HIV-1-infected PBMC cultures
Number of subjects: 44
Study 11566624 — intervention group
Group type: EXPERIMENTAL
Intervention: iNOS specific inhibitors
Number of subjects: 44
Study 11566624 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutralising anti-TNF-alpha monoclonal antibody
Number of subjects: 44
Study 11566624 — intervention group
Group type: COMPARATOR
Intervention: Plasma TNF-alpha and NO levels in HIV-1-infected children
Number of subjects: 44
Study 11566624 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1-infected children with higher viral load (> 4.7 log10)
Number of subjects: 44
Study 9596400 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG-triggered neuromuscular stimulation (EMG-stim)
Number of subjects: 9
Study 9596400 — intervention group
Group type: COMPARATOR
Intervention: Control (no EMG-stim)
Number of subjects: 9
Study 8181202 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotinine (30 mg) intravenously
Number of subjects: 0
Study 8181202 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3651943 — intervention group
Group type: EXPERIMENTAL
Intervention: One-dose regimen of trivalent inactivated whole-virion influenza vaccine (0.5 ml, containing 15 micrograms of hemagglutinin of each antigen)
Number of subjects: 102
Study 3651943 — intervention group
Group type: COMPARATOR
Intervention: Two-dose regimen of trivalent inactivated whole-virion influenza vaccine (0.5 ml, second dose administered 8 weeks after the first)
Number of subjects: 102
Study 29931447 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-loss maintainers (≥10% weight loss maintained at 6 months)
Number of subjects: 58
Study 29931447 — intervention group
Group type: COMPARATOR
Intervention: Weight-loss regainers (did not maintain >10% weight loss at 6 months)
Number of subjects: 58
Study 29931447 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet adherence after the initial 11 weeks
Number of subjects: 58
Study 29931447 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss at 15 weeks
Number of subjects: 58
Study 29931447 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-loss satisfaction from week 15 or 19
Number of subjects: 58
Study 29931447 — intervention group
Group type: EXPERIMENTAL
Intervention: 11-week dietary adherence and 15-week weight loss
Number of subjects: 58
Study 30420123 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir (50 mg) plus lamivudine (300 mg)
Number of subjects: 1441
Study 30420123 — intervention group
Group type: COMPARATOR
Intervention: Dolutegravir (50 mg) plus tenofovir disoproxil fumarate (300 mg) and emtricitabine (200 mg)
Number of subjects: 1441
Study 30420123 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-drug regimen
Number of subjects: 1441
Study 30420123 — intervention group
Group type: COMPARATOR
Intervention: Three-drug regimen
Number of subjects: 1441
Study 29990851 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (2 mg/kg) based on total body weight (TBW)
Number of subjects: 0
Study 29990851 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (2 mg/kg) based on lean body weight (LBW)
Number of subjects: 0
Study 29990851 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 26116635 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy (kinesitherapy and electrotherapeutic procedures) including medicamentous therapy, walking exercises beyond the pain threshold, dynamic low‐burden kinesi exercises, interference therapy, diadynamic therapy, and electromagnetic field.
Number of subjects: 47
Study 26116635 — intervention group
Group type: COMPARATOR
Intervention: Conventional non‐operative treatment including medicamentous therapy and walking exercises.
Number of subjects: 47
Study 25144438 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial-body cryotherapy (3 min at -110°C)
Number of subjects: 12
Study 25144438 — intervention group
Group type: COMPARATOR
Intervention: Control (no cryotherapy)
Number of subjects: 12
Study 22357724 — intervention group
Group type: COMPARATOR
Intervention: CMF+glu
Number of subjects: 30
Study 22357724 — intervention group
Group type: COMPARATOR
Intervention: ePHF
Number of subjects: 30
Study 22357724 — intervention group
Group type: EXPERIMENTAL
Intervention: CMF
Number of subjects: 30
Study 19593418 — intervention group
Group type: COMPARATOR
Intervention: No ankle brace (NB)
Number of subjects: 28
Study 19593418 — intervention group
Group type: EXPERIMENTAL
Intervention: Lace-up brace (LU)
Number of subjects: 28
Study 19593418 — intervention group
Group type: EXPERIMENTAL
Intervention: Semirigid brace (SR)
Number of subjects: 28
Study 19593418 — intervention group
Group type: COMPARATOR
Intervention: Stable group
Number of subjects: 28
Study 19593418 — intervention group
Group type: EXPERIMENTAL
Intervention: Unstable group
Number of subjects: 28
Study 19593418 — intervention group
Group type: EXPERIMENTAL
Intervention: All brace conditions
Number of subjects: 28
Study 17488793 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH (0.46 mg/kg.wk) in daily sc injections
Number of subjects: 30
Study 17488793 — intervention group
Group type: COMPARATOR
Intervention: No rhGH therapy
Number of subjects: 30
Study 17488793 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH treatment
Number of subjects: 30
Study 15061962 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (1.5 mg/kg, 2 mg/kg, and 3 mg/kg)
Number of subjects: 150
Study 15061962 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.2 mg/kg, 0.3 mg/kg, and 0.4 mg/kg)
Number of subjects: 150
Study 15061962 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate (0.15 mg/kg, 0.3 mg/kg, and 0.4 mg/kg)
Number of subjects: 150
Study 15061962 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalational anesthetics (enflurane, isoflurane, desflurane) at concentrations corresponding to 0 to 0.3, 0.5, 0.75, 1.0 and 1.5 MAC
Number of subjects: 150
Study 11553254 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal tube
Number of subjects: 34
Study 11553254 — intervention group
Group type: COMPARATOR
Intervention: Laryngeal mask
Number of subjects: 34
Study 9745140 — intervention group
Group type: EXPERIMENTAL
Intervention: Micanol monotherapy
Number of subjects: 36
Study 9745140 — intervention group
Group type: EXPERIMENTAL
Intervention: Micanol in combination with UVB phototherapy
Number of subjects: 36
Study 9745140 — intervention group
Group type: COMPARATOR
Intervention: Placebo combined with UVB phototherapy
Number of subjects: 36
Study 7700066 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibition of the angiotensin-converting enzyme
Number of subjects: 0
Study 3191761 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized albuterol
Number of subjects: 28
Study 3191761 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized metaproterenol
Number of subjects: 28
Study 3191761 — intervention group
Group type: COMPARATOR
Intervention: MDI with InspirEase
Number of subjects: 28
Study 3191761 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including MDI and nebulizer regimens)
Number of subjects: 28
Study 29865075 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-domain intervention plus placebo
Number of subjects: 1293
Study 29865075 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated multi-domain intervention
Number of subjects: 1293
Study 29865075 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 PUFA
Number of subjects: 1293
Study 29865075 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1293
Study 27419367 — intervention group
Group type: EXPERIMENTAL
Intervention: TETRA exposure during chest exposure in the first experiment.
Number of subjects: 0
Study 27419367 — intervention group
Group type: EXPERIMENTAL
Intervention: TETRA exposure during chest exposure in the second experiment.
Number of subjects: 0
Study 27419367 — intervention group
Group type: COMPARATOR
Intervention: Sham exposure (control) in both experiments.
Number of subjects: 0
Study 24061847 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibialis anterior tendon transfer surgery
Number of subjects: 20
Study 24061847 — intervention group
Group type: COMPARATOR
Intervention: Control group (casting only)
Number of subjects: 20
Study 23319529 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-hour web-based tobacco cessation education program (WeBREATHe)
Number of subjects: 215
Study 23319529 — intervention group
Group type: COMPARATOR
Intervention: Delayed training (control)
Number of subjects: 215
Study 20127530 — intervention group
Group type: EXPERIMENTAL
Intervention: Central neuraxial blockade (anesthetic dose)
Number of subjects: 681
Study 20127530 — intervention group
Group type: EXPERIMENTAL
Intervention: Central neuraxial blockade (analgesic dose)
Number of subjects: 681
Study 20127530 — intervention group
Group type: EXPERIMENTAL
Intervention: Central neuraxial blockade (overall)
Number of subjects: 681
Study 18716414 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg) and folic acid (10 mg/day) for 6 weeks
Number of subjects: 27
Study 18716414 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine and placebo for 6 weeks
Number of subjects: 27
Study 16631047 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracameral cefuroxime
Number of subjects: 13698
Study 16631047 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative levofloxacin eyedrops
Number of subjects: 13698
Study 16631047 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis (Control)
Number of subjects: 13698
Study 12455569 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) therapy 6,000 U/week for 6 months
Number of subjects: 22
Study 10510547 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial ablation
Number of subjects: 50
Study 8750052 — intervention group
Group type: EXPERIMENTAL
Intervention: Korean red ginseng
Number of subjects: 90
Study 8750052 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 8750052 — intervention group
Group type: COMPARATOR
Intervention: Trazodone
Number of subjects: 90
Study 1844569 — intervention group
Group type: EXPERIMENTAL
Intervention: ATP‐E supplementation
Number of subjects: 23
Study 1844569 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 7023744 — intervention group
Group type: EXPERIMENTAL
Intervention: prazosin
Number of subjects: 232
Study 7023744 — intervention group
Group type: COMPARATOR
Intervention: hydralazine
Number of subjects: 232
Study 31589891 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 121
Study 31589891 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 30673911 — intervention group
Group type: EXPERIMENTAL
Intervention: Teacher ratings on the Adaptive Behavior Assessment System (ABAS)
Number of subjects: 103
Study 30673911 — intervention group
Group type: COMPARATOR
Intervention: Parent ratings on the Adaptive Behavior Assessment System (ABAS)
Number of subjects: 103
Study 30673911 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between parent and teacher scores
Number of subjects: 103
Study 30673911 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-teacher agreement analysis
Number of subjects: 103
Study 30673911 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderators of difference scores
Number of subjects: 103
Study 28729329 — intervention group
Group type: EXPERIMENTAL
Intervention: Low chloride fluid strategy
Number of subjects: 100
Study 28729329 — intervention group
Group type: COMPARATOR
Intervention: High chloride fluid strategy
Number of subjects: 100
Study 25040164 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial stimulation (PS)
Number of subjects: 507
Study 25040164 — intervention group
Group type: EXPERIMENTAL
Intervention: Food supplementation (FS)
Number of subjects: 507
Study 25040164 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial stimulation + Food supplementation (PS+FS)
Number of subjects: 507
Study 25040164 — intervention group
Group type: COMPARATOR
Intervention: Clinic control (CC)
Number of subjects: 507
Study 25040164 — intervention group
Group type: COMPARATOR
Intervention: Hospital control (CH)
Number of subjects: 507
Study 23487539 — intervention group
Group type: EXPERIMENTAL
Intervention: CCL21 levels measured at randomization
Number of subjects: 2601
Study 21652290 — intervention group
Group type: EXPERIMENTAL
Intervention: Chimney stove
Number of subjects: 266
Study 21652290 — intervention group
Group type: COMPARATOR
Intervention: Open fire
Number of subjects: 266
Study 19552017 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac and famotidin
Number of subjects: 224
Study 19552017 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac only
Number of subjects: 224
Study 17785672 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam 10, 20, 40, or 80 mg
Number of subjects: 18
Study 17785672 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 17785672 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam 80 mg
Number of subjects: 18
Study 17785672 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam
Number of subjects: 18
Study 15553820 — intervention group
Group type: EXPERIMENTAL
Intervention: bushen tiaogan qingxin recipe (BTQR)
Number of subjects: 40
Study 15553820 — intervention group
Group type: COMPARATOR
Intervention: hormone replacement therapy (HRT)
Number of subjects: 40
Study 11684374 — intervention group
Group type: EXPERIMENTAL
Intervention: Calisthenic home exercises
Number of subjects: 137
Study 11684374 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 137
Study 10207795 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon therapy (10 MU/m2 of lymphoblastoid interferon alfa 3 times per week for 12 weeks)
Number of subjects: 45
Study 10207795 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 45
Study 8998405 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical stress stimuli
Number of subjects: 18
Study 8998405 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological stress stimuli
Number of subjects: 18
Study 8998405 — intervention group
Group type: COMPARATOR
Intervention: Control session (no stress stimulus)
Number of subjects: 18
Study 2205259 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 5-fluorouracil (5-FU) and plasma perfusion (PP) over protein A-Sepharose (group A)
Number of subjects: 30
Study 2205259 — intervention group
Group type: COMPARATOR
Intervention: Combination of 5-FU and PP over sepharose (group B)
Number of subjects: 30
Study 2205259 — intervention group
Group type: COMPARATOR
Intervention: 5-FU alone (group C)
Number of subjects: 30
Study 118024 — intervention group
Group type: EXPERIMENTAL
Intervention: Corn oil diet
Number of subjects: 12
Study 118024 — intervention group
Group type: COMPARATOR
Intervention: Palm oil diet
Number of subjects: 12
Study 118024 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 12
Study 31634603 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacomechanical therapy
Number of subjects: 97
Study 29733435 — intervention group
Group type: EXPERIMENTAL
Intervention: Imarikiren 80 mg (nonelderly)
Number of subjects: 100
Study 29733435 — intervention group
Group type: EXPERIMENTAL
Intervention: Imarikiren 160 mg (nonelderly)
Number of subjects: 100
Study 29733435 — intervention group
Group type: EXPERIMENTAL
Intervention: Imarikiren 80 mg (elderly)
Number of subjects: 100
Study 29733435 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 26872902 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-operative specimen mammography (ISM)
Number of subjects: 72
Study 26872902 — intervention group
Group type: COMPARATOR
Intervention: Standard specimen mammography (SSM)
Number of subjects: 72
Study 24886163 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy (IMRT)
Number of subjects: 5
Study 24886163 — intervention group
Group type: EXPERIMENTAL
Intervention: Volumetric arc therapy (VMAT)
Number of subjects: 5
Study 24886163 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomotherapy (TOMO)
Number of subjects: 5